AC Immune SA

6.67+0.0500+0.76%Vol 171.36K1Y Perf -6.68%
Apr 13th, 2021 16:00 DELAYED
BID6.61 ASK6.98
Open6.62 Previous Close6.62
Pre-Market- After-Market-
 - -  - -%
Target Price
15.50 
Analyst Rating
Strong Buy 1.00
Potential %
132.38 
Finscreener Ranking
★★★★★     59.28
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     54.03
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     61.17
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap479.82M 
Earnings Rating
Neutral
Price Range Ratio 52W %
26.22 
Earnings Date
3rd May 2021

Today's Price Range

6.556.82

52W Range

4.4213.00

5 Year PE Ratio Range

-43.9054.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.85%
1 Month
-14.49%
3 Months
8.99%
6 Months
34.48%
1 Year
-6.68%
3 Years
-25.39%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ACIU6.670.05000.76
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
16.30
16.50
0.01
0.01
-335.50
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-386.40
-374.40
-245.90
-51.92
RevenueValueIndustryS&P 500US Markets
4.57M
0.06
25.97
-0.91
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.29-0.30-3.45
Q03 2020-0.24-0.28-16.67
Q02 2020-0.28-0.2317.86
Q01 2020-0.17-0.1041.18
Q04 2019-0.22-0.28-27.27
Q03 2019-0.060.25516.67
Q02 2019-0.24-0.234.17
Q01 20191.340.84-37.31
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.2167.69Positive
6/2021 QR-0.2171.62Positive
12/2021 FY-0.46--
12/2022 FY-0.09--
Next Report Date3rd May 2021
Estimated EPS Next Report-0.21
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume171.36K
Shares Outstanding71.94M
Trades Count1.06K
Dollar Volume6.55M
Avg. Volume901.58K
Avg. Weekly Volume157.44K
Avg. Monthly Volume257.41K
Avg. Quarterly Volume945.41K

AC Immune SA (NASDAQ: ACIU) stock closed at 6.67 per share at the end of the most recent trading day (a 0.76% change compared to the prior day closing price) with a volume of 171.38K shares and market capitalization of 479.82M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 132 people. AC Immune SA CEO is Andrea Pfeifer.

The one-year performance of AC Immune SA stock is -6.68%, while year-to-date (YTD) performance is 29.01%. ACIU stock has a five-year performance of %. Its 52-week range is between 4.42 and 13, which gives ACIU stock a 52-week price range ratio of 26.22%

AC Immune SA currently has a PE ratio of -7.20, a price-to-book (PB) ratio of 2.17, a price-to-sale (PS) ratio of 108.06, a price to cashflow ratio of 8.90, a PEG ratio of 2.32, a ROA of -23.12%, a ROC of -23.25% and a ROE of -25.49%. The company’s profit margin is -51.92%, its EBITDA margin is -374.40%, and its revenue ttm is $4.57 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from AC Immune SA, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. AC Immune SA’s next earnings report date is 03rd May 2021.

The consensus rating of Wall Street analysts for AC Immune SA is Strong Buy (1), with a target price of $15.5, which is +132.38% compared to the current price. The earnings rating for AC Immune SA stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AC Immune SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AC Immune SA has a Sell technical analysis rating based on Technical Indicators (ADX : 37.50, ATR14 : 0.68, CCI20 : -155.98, Chaikin Money Flow : -0.17, MACD : 0.03, Money Flow Index : 50.20, ROC : -14.05, RSI : 49.86, STOCH (14,3) : 10.30, STOCH RSI : 0.16, UO : 32.01, Williams %R : -89.70), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AC Immune SA in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

CEO: Andrea Pfeifer

Telephone: +41 216939121

Address: EPFL Innovation Park, Lausanne 1015, , CH

Number of employees: 132

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

51%49%

Bearish Bullish

60%40%

News

Stocktwits